


## **Coding Brief: New Codes for Administration of RSV Immunoglobulin**

### **CPT® Assistant.**


**November 2023; Volume 33: Issue 11**

During the September 2023 CPT Editorial Panel meeting, two new codes (96380, 96381) were established within the Therapeutic, Prophylactic, and Diagnostic Injections and Infusions subsection of the Medicine section to describe counseling and administration of the new respiratory syncytial virus (RSV) monoclonal antibody product represented by codes 90380 and 90381. Given the need to have these administration codes in place for the upcoming RSV season, the codes were released early to the American Medical Association (AMA) website and effective as of October 6, 2023. This coding brief provides an overview of codes 96380 and 96381 and their appropriate usage.

### **Therapeutic, Prophylactic, and Diagnostic Injections and Infusions**

# **96380** Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional

 (Report 96380 for administration of respiratory syncytial virus, monoclonal antibody, seasonal dose [90380, 90381])

# **96381** Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection

 (Report 96381 for administration of respiratory syncytial virus, monoclonal antibody, seasonal dose [90380, 90381])

According to the Centers for Disease Control and Prevention (CDC), this RSV monoclonal antibody (generic name nirsevimab) has been approved by the Food and Drug Administration (FDA) and recommended by the Advisory Committee on Immunization Practices (ACIP) to be administered to infants under 8 months of age during their first RSV season, and to children 8 months through 19 months of age who are at increased risk of severe RSV disease during their second RSV season.<sup>1</sup> As infants and children meeting these criteria are not able to receive a traditional vaccine for RSV, administration of this monoclonal antibody provides passive immunization against RSV, which helps prevent disease in this vulnerable population.

Code 96380 should be reported when counseling is provided to the parent or guardian of a child and the parent or guardian agrees to the child receiving the RSV monoclonal antibody. Code 96381 should be reported when the parent or guardian of a child brings the child in to receive the RSV monoclonal antibody only and counseling was not provided at the time of administration. Parenthetical notes for both codes provide guidance on appropriate reporting instructions. Descriptors for these codes may be found on the AMA website at <https://www.ama-assn.org/practice-management/cpt/category-i-immunization-codes>.

The following clinical examples and procedural descriptions reflect typical clinical scenarios for which these new codes would be appropriately reported.

### **Clinical Example (96380)**

The parent or guardian of a 6-month-old female presents with the child during the fall season for seasonal immunization. The physician or other qualified healthcare professional (QHP) provides benefit and risk counseling on immunization for the seasonal respiratory syncytial virus (RSV) to the parent or guardian and answers all their questions. The parent or guardian agrees to have their child receive the product.

### **Description of Procedure (96380)**

The physician or QHP recommends passive immunization with the RSV immune globulin seasonal product for protection against RSV during the child's vulnerable first year. Counsel the parent or guardian on the benefits and risks, answer all their questions, and obtain consent. Following the administration of the injection, monitor the patient for any adverse reaction. Discuss the care plan for the child with the parent or guardian in the days to follow specific to



the anticipated or possible side effects (eg, soreness and pain at the injection site, fever) and review the signs or symptoms that warrant a callback.

### **Clinical Example (96381)**

The parent or guardian of a 6-month-old female seeks immunization against seasonal RSV for the child. The parent or guardian is offered and accepts an intramuscular injection of the RSV monoclonal antibody for the child.

### **Description of Procedure (96381)**

The physician or QHP recommends passive immunization with the RSV immune globulin seasonal product for protection against RSV during the child's vulnerable first year. Obtain consent from the parent or guardian. Following the administration of the injection, monitor the patient for any adverse reaction.